Loading…

The atypical antipsychotic profile of NRA0045, a novel dopamine D 4 and 5‐hydroxytryptamine 2A receptor antagonist, in rats

The atypical antipsychotic profile of ( R )‐(+)‐2‐amino‐4‐(4‐fluorophenyl)‐5‐[1‐[4‐(4‐fluorophenyl)‐4‐oxobutyl] pyrrolidin‐3‐yl] thiazole (NRA0045), a potent dopamine D 4 and 5‐hydroxytryptamine (5‐HT) 2A receptor antagonist, was examined in rats. Spontaneous locomotor activity was decreased dose‐de...

Full description

Saved in:
Bibliographic Details
Published in:British journal of pharmacology 2009-02, Vol.121 (3), p.515-525
Main Authors: Okuyama, Shigeru, Chaki, Shigeyuki, Kawashima, Naoya, Suzuki, Yoshiko, Ogawa, Shin‐ichi, Kumagai, Toshihito, Nakazato, Atsuro, Nagamine, Masashi, Yamaguchi, Kazumasa, Tomisawa, Kazuyuki
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c844-98d578226f9adcb091fcf232e61d35ae311f526c57072f396e74ff7b544e1cc03
cites cdi_FETCH-LOGICAL-c844-98d578226f9adcb091fcf232e61d35ae311f526c57072f396e74ff7b544e1cc03
container_end_page 525
container_issue 3
container_start_page 515
container_title British journal of pharmacology
container_volume 121
creator Okuyama, Shigeru
Chaki, Shigeyuki
Kawashima, Naoya
Suzuki, Yoshiko
Ogawa, Shin‐ichi
Kumagai, Toshihito
Nakazato, Atsuro
Nagamine, Masashi
Yamaguchi, Kazumasa
Tomisawa, Kazuyuki
description The atypical antipsychotic profile of ( R )‐(+)‐2‐amino‐4‐(4‐fluorophenyl)‐5‐[1‐[4‐(4‐fluorophenyl)‐4‐oxobutyl] pyrrolidin‐3‐yl] thiazole (NRA0045), a potent dopamine D 4 and 5‐hydroxytryptamine (5‐HT) 2A receptor antagonist, was examined in rats. Spontaneous locomotor activity was decreased dose‐dependently with i.p. administration of clozapine (ED 50 3.7 mg kg −1 ), haloperidol (ED 50 0.1 mg kg −1 ) and chlorpromazine (ED 50 0.9 mg kg −1 ), whereas inhibition of this type of behaviour induced by i.p. administration of NRA0045, at doses up to 10 mg kg −1 , did not exceed 50%. Locomotor hyperactivity induced by methamphetamine (MAP, 2 mg kg −1 , i.p.) in rats (a model of antipsychotic activity) was dose‐dependently antagonized by NRA0045 (ED 50 0.4 mg kg −1 , i.p., and 0.3 mg kg −1 , p.o., respectively), clozapine (ED 50 0.3 mg kg −1 , i.p. and 0.8 mg kg −1 , p.o., respectively), haloperidol (ED 50 0.02 mg kg −1 , i.p. and 0.1 mg kg −1 , p.o., respectively), chlorpromazine (ED 50 0.3 mg kg −1 , i.p. and 3.3 mg kg −1 , p.o., respectively). In contrast, the MAP (3 mg kg −1 , i.v.)‐induced stereotyped behaviour in rats (a model of extrapyramidal symptoms) was not affected by NRA0045 or clozapine, at the highest dose given (30 mg kg −1 , i.p.). Haloperidol (ED 50 0.3 mg kg −1 , i.p.) and chlorpromazine (ED 50 4.8 mg kg −1 , i.p.) strongly blocked the MAP‐induced stereotyped behaviour. NRA0045 and clozapine selectively blocked behaviour associated with activation of the mesolimbic/mesocortical dopamine neurones rather than nigrostriatal dopamine neurones. Extracellular single‐unit recording studies demonstrated that MAP (1 mg kg −1 , i.v.) decreased the firing rate in the substantia nigra (A9) and ventral tegmental area (A10) dopamine neurones in anaesthetized rats. NRA0045 completely reversed the inhibitory effects of MAP on A10 dopamine neurones (ED 50 0.1 mg kg −1 , i.v.), whereas the inhibitory effects of MAP on A9 dopamine neurones were not affected by NRA0045, in doses up to 1 mg kg −1 (i.v.). Clozapine completely reversed the inhibitory effects of MAP on A10 dopamine neurones (ED 50 1.9 mg kg −1 , i.v.) and on A9 dopamine neurones (ED 50 2.5 mg kg −1 , i.v.). Haloperidol completely reversed the inhibitory effects of MAP on A10 (ED 50 0.03 mg kg −1 , i.v.) and on A9 dopamine neurones (0.02 mg kg −1 , i.v.). NRA0045, like clozapine, was more potent in reversing the effects of MAP on A10 than A9 dopamine neurones. Prepulse inhibition (PPI) is impaired marke
doi_str_mv 10.1038/sj.bjp.0701164
format article
fullrecord <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1038_sj_bjp_0701164</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1038_sj_bjp_0701164</sourcerecordid><originalsourceid>FETCH-LOGICAL-c844-98d578226f9adcb091fcf232e61d35ae311f526c57072f396e74ff7b544e1cc03</originalsourceid><addsrcrecordid>eNotkE9LwzAchoMoOKdXz_kAa_2lSZr2OOZfGArSe8nSxKV0TUiC2IPgR_Az-knc2E7v4eF9Dg9CtwRyArS6i32-6X0OAggp2RmaESbKjNOKnKMZAIiMkKq6RFcx9gB7KPgMfTdbjWWavFVywHJM1sdJbV2yCvvgjB00dga_vi8BGF9giUf3qQfcOS93dtT4HrP9rcP87-d3O3XBfU0pTD4dabHEQSvtkwsHufxwo41pge2Ig0zxGl0YOUR9c9o5ah4fmtVztn57elkt15mqGMvqquOiKorS1LJTG6iJUaaghS5JR7nUlBDDi1JxAaIwtC61YMaIDWdME6WAzlF-1KrgYgzatD7YnQxTS6A9tGtj3-7btad29B9ZUmRs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>The atypical antipsychotic profile of NRA0045, a novel dopamine D 4 and 5‐hydroxytryptamine 2A receptor antagonist, in rats</title><source>Wiley</source><source>PubMed Central</source><creator>Okuyama, Shigeru ; Chaki, Shigeyuki ; Kawashima, Naoya ; Suzuki, Yoshiko ; Ogawa, Shin‐ichi ; Kumagai, Toshihito ; Nakazato, Atsuro ; Nagamine, Masashi ; Yamaguchi, Kazumasa ; Tomisawa, Kazuyuki</creator><creatorcontrib>Okuyama, Shigeru ; Chaki, Shigeyuki ; Kawashima, Naoya ; Suzuki, Yoshiko ; Ogawa, Shin‐ichi ; Kumagai, Toshihito ; Nakazato, Atsuro ; Nagamine, Masashi ; Yamaguchi, Kazumasa ; Tomisawa, Kazuyuki</creatorcontrib><description>The atypical antipsychotic profile of ( R )‐(+)‐2‐amino‐4‐(4‐fluorophenyl)‐5‐[1‐[4‐(4‐fluorophenyl)‐4‐oxobutyl] pyrrolidin‐3‐yl] thiazole (NRA0045), a potent dopamine D 4 and 5‐hydroxytryptamine (5‐HT) 2A receptor antagonist, was examined in rats. Spontaneous locomotor activity was decreased dose‐dependently with i.p. administration of clozapine (ED 50 3.7 mg kg −1 ), haloperidol (ED 50 0.1 mg kg −1 ) and chlorpromazine (ED 50 0.9 mg kg −1 ), whereas inhibition of this type of behaviour induced by i.p. administration of NRA0045, at doses up to 10 mg kg −1 , did not exceed 50%. Locomotor hyperactivity induced by methamphetamine (MAP, 2 mg kg −1 , i.p.) in rats (a model of antipsychotic activity) was dose‐dependently antagonized by NRA0045 (ED 50 0.4 mg kg −1 , i.p., and 0.3 mg kg −1 , p.o., respectively), clozapine (ED 50 0.3 mg kg −1 , i.p. and 0.8 mg kg −1 , p.o., respectively), haloperidol (ED 50 0.02 mg kg −1 , i.p. and 0.1 mg kg −1 , p.o., respectively), chlorpromazine (ED 50 0.3 mg kg −1 , i.p. and 3.3 mg kg −1 , p.o., respectively). In contrast, the MAP (3 mg kg −1 , i.v.)‐induced stereotyped behaviour in rats (a model of extrapyramidal symptoms) was not affected by NRA0045 or clozapine, at the highest dose given (30 mg kg −1 , i.p.). Haloperidol (ED 50 0.3 mg kg −1 , i.p.) and chlorpromazine (ED 50 4.8 mg kg −1 , i.p.) strongly blocked the MAP‐induced stereotyped behaviour. NRA0045 and clozapine selectively blocked behaviour associated with activation of the mesolimbic/mesocortical dopamine neurones rather than nigrostriatal dopamine neurones. Extracellular single‐unit recording studies demonstrated that MAP (1 mg kg −1 , i.v.) decreased the firing rate in the substantia nigra (A9) and ventral tegmental area (A10) dopamine neurones in anaesthetized rats. NRA0045 completely reversed the inhibitory effects of MAP on A10 dopamine neurones (ED 50 0.1 mg kg −1 , i.v.), whereas the inhibitory effects of MAP on A9 dopamine neurones were not affected by NRA0045, in doses up to 1 mg kg −1 (i.v.). Clozapine completely reversed the inhibitory effects of MAP on A10 dopamine neurones (ED 50 1.9 mg kg −1 , i.v.) and on A9 dopamine neurones (ED 50 2.5 mg kg −1 , i.v.). Haloperidol completely reversed the inhibitory effects of MAP on A10 (ED 50 0.03 mg kg −1 , i.v.) and on A9 dopamine neurones (0.02 mg kg −1 , i.v.). NRA0045, like clozapine, was more potent in reversing the effects of MAP on A10 than A9 dopamine neurones. Prepulse inhibition (PPI) is impaired markedly in humans with schizophrenia. The disruption of PPI in rats by apomorphine (0.5 mg kg −1 , s.c.) was reversed significantly by NRA0045 (3 mg kg −1 , i.p.), clozapine (3 mg kg −1 , i.p.) and haloperidol (0.3 mg kg −1 , i.p.). Phencyclidine (PCP) elicits predominantly psychotic symptoms in normal humans and in schizophrenics. NRA0045 (0.03–0.3 mg kg −1 , i.p.) and clozapine (0.1–1 mg kg −1 , i.p.) significantly and dose‐dependently shortened the PCP(1.25 mg kg −1 , i.p.)‐induced prolonged swimming latency in rats in a water maze task, whereas haloperidol (0.01–0.1 mg kg −1 , i.p.) did not significantly alter swimming latency. These findings suggest that NRA0045 may have unique antipsychotic activities without the liability of motor side effects typical of classical antipsychotics.</description><identifier>ISSN: 0007-1188</identifier><identifier>EISSN: 1476-5381</identifier><identifier>DOI: 10.1038/sj.bjp.0701164</identifier><language>eng</language><ispartof>British journal of pharmacology, 2009-02, Vol.121 (3), p.515-525</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c844-98d578226f9adcb091fcf232e61d35ae311f526c57072f396e74ff7b544e1cc03</citedby><cites>FETCH-LOGICAL-c844-98d578226f9adcb091fcf232e61d35ae311f526c57072f396e74ff7b544e1cc03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27911,27912</link.rule.ids></links><search><creatorcontrib>Okuyama, Shigeru</creatorcontrib><creatorcontrib>Chaki, Shigeyuki</creatorcontrib><creatorcontrib>Kawashima, Naoya</creatorcontrib><creatorcontrib>Suzuki, Yoshiko</creatorcontrib><creatorcontrib>Ogawa, Shin‐ichi</creatorcontrib><creatorcontrib>Kumagai, Toshihito</creatorcontrib><creatorcontrib>Nakazato, Atsuro</creatorcontrib><creatorcontrib>Nagamine, Masashi</creatorcontrib><creatorcontrib>Yamaguchi, Kazumasa</creatorcontrib><creatorcontrib>Tomisawa, Kazuyuki</creatorcontrib><title>The atypical antipsychotic profile of NRA0045, a novel dopamine D 4 and 5‐hydroxytryptamine 2A receptor antagonist, in rats</title><title>British journal of pharmacology</title><description>The atypical antipsychotic profile of ( R )‐(+)‐2‐amino‐4‐(4‐fluorophenyl)‐5‐[1‐[4‐(4‐fluorophenyl)‐4‐oxobutyl] pyrrolidin‐3‐yl] thiazole (NRA0045), a potent dopamine D 4 and 5‐hydroxytryptamine (5‐HT) 2A receptor antagonist, was examined in rats. Spontaneous locomotor activity was decreased dose‐dependently with i.p. administration of clozapine (ED 50 3.7 mg kg −1 ), haloperidol (ED 50 0.1 mg kg −1 ) and chlorpromazine (ED 50 0.9 mg kg −1 ), whereas inhibition of this type of behaviour induced by i.p. administration of NRA0045, at doses up to 10 mg kg −1 , did not exceed 50%. Locomotor hyperactivity induced by methamphetamine (MAP, 2 mg kg −1 , i.p.) in rats (a model of antipsychotic activity) was dose‐dependently antagonized by NRA0045 (ED 50 0.4 mg kg −1 , i.p., and 0.3 mg kg −1 , p.o., respectively), clozapine (ED 50 0.3 mg kg −1 , i.p. and 0.8 mg kg −1 , p.o., respectively), haloperidol (ED 50 0.02 mg kg −1 , i.p. and 0.1 mg kg −1 , p.o., respectively), chlorpromazine (ED 50 0.3 mg kg −1 , i.p. and 3.3 mg kg −1 , p.o., respectively). In contrast, the MAP (3 mg kg −1 , i.v.)‐induced stereotyped behaviour in rats (a model of extrapyramidal symptoms) was not affected by NRA0045 or clozapine, at the highest dose given (30 mg kg −1 , i.p.). Haloperidol (ED 50 0.3 mg kg −1 , i.p.) and chlorpromazine (ED 50 4.8 mg kg −1 , i.p.) strongly blocked the MAP‐induced stereotyped behaviour. NRA0045 and clozapine selectively blocked behaviour associated with activation of the mesolimbic/mesocortical dopamine neurones rather than nigrostriatal dopamine neurones. Extracellular single‐unit recording studies demonstrated that MAP (1 mg kg −1 , i.v.) decreased the firing rate in the substantia nigra (A9) and ventral tegmental area (A10) dopamine neurones in anaesthetized rats. NRA0045 completely reversed the inhibitory effects of MAP on A10 dopamine neurones (ED 50 0.1 mg kg −1 , i.v.), whereas the inhibitory effects of MAP on A9 dopamine neurones were not affected by NRA0045, in doses up to 1 mg kg −1 (i.v.). Clozapine completely reversed the inhibitory effects of MAP on A10 dopamine neurones (ED 50 1.9 mg kg −1 , i.v.) and on A9 dopamine neurones (ED 50 2.5 mg kg −1 , i.v.). Haloperidol completely reversed the inhibitory effects of MAP on A10 (ED 50 0.03 mg kg −1 , i.v.) and on A9 dopamine neurones (0.02 mg kg −1 , i.v.). NRA0045, like clozapine, was more potent in reversing the effects of MAP on A10 than A9 dopamine neurones. Prepulse inhibition (PPI) is impaired markedly in humans with schizophrenia. The disruption of PPI in rats by apomorphine (0.5 mg kg −1 , s.c.) was reversed significantly by NRA0045 (3 mg kg −1 , i.p.), clozapine (3 mg kg −1 , i.p.) and haloperidol (0.3 mg kg −1 , i.p.). Phencyclidine (PCP) elicits predominantly psychotic symptoms in normal humans and in schizophrenics. NRA0045 (0.03–0.3 mg kg −1 , i.p.) and clozapine (0.1–1 mg kg −1 , i.p.) significantly and dose‐dependently shortened the PCP(1.25 mg kg −1 , i.p.)‐induced prolonged swimming latency in rats in a water maze task, whereas haloperidol (0.01–0.1 mg kg −1 , i.p.) did not significantly alter swimming latency. These findings suggest that NRA0045 may have unique antipsychotic activities without the liability of motor side effects typical of classical antipsychotics.</description><issn>0007-1188</issn><issn>1476-5381</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNotkE9LwzAchoMoOKdXz_kAa_2lSZr2OOZfGArSe8nSxKV0TUiC2IPgR_Az-knc2E7v4eF9Dg9CtwRyArS6i32-6X0OAggp2RmaESbKjNOKnKMZAIiMkKq6RFcx9gB7KPgMfTdbjWWavFVywHJM1sdJbV2yCvvgjB00dga_vi8BGF9giUf3qQfcOS93dtT4HrP9rcP87-d3O3XBfU0pTD4dabHEQSvtkwsHufxwo41pge2Ig0zxGl0YOUR9c9o5ah4fmtVztn57elkt15mqGMvqquOiKorS1LJTG6iJUaaghS5JR7nUlBDDi1JxAaIwtC61YMaIDWdME6WAzlF-1KrgYgzatD7YnQxTS6A9tGtj3-7btad29B9ZUmRs</recordid><startdate>20090210</startdate><enddate>20090210</enddate><creator>Okuyama, Shigeru</creator><creator>Chaki, Shigeyuki</creator><creator>Kawashima, Naoya</creator><creator>Suzuki, Yoshiko</creator><creator>Ogawa, Shin‐ichi</creator><creator>Kumagai, Toshihito</creator><creator>Nakazato, Atsuro</creator><creator>Nagamine, Masashi</creator><creator>Yamaguchi, Kazumasa</creator><creator>Tomisawa, Kazuyuki</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20090210</creationdate><title>The atypical antipsychotic profile of NRA0045, a novel dopamine D 4 and 5‐hydroxytryptamine 2A receptor antagonist, in rats</title><author>Okuyama, Shigeru ; Chaki, Shigeyuki ; Kawashima, Naoya ; Suzuki, Yoshiko ; Ogawa, Shin‐ichi ; Kumagai, Toshihito ; Nakazato, Atsuro ; Nagamine, Masashi ; Yamaguchi, Kazumasa ; Tomisawa, Kazuyuki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c844-98d578226f9adcb091fcf232e61d35ae311f526c57072f396e74ff7b544e1cc03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Okuyama, Shigeru</creatorcontrib><creatorcontrib>Chaki, Shigeyuki</creatorcontrib><creatorcontrib>Kawashima, Naoya</creatorcontrib><creatorcontrib>Suzuki, Yoshiko</creatorcontrib><creatorcontrib>Ogawa, Shin‐ichi</creatorcontrib><creatorcontrib>Kumagai, Toshihito</creatorcontrib><creatorcontrib>Nakazato, Atsuro</creatorcontrib><creatorcontrib>Nagamine, Masashi</creatorcontrib><creatorcontrib>Yamaguchi, Kazumasa</creatorcontrib><creatorcontrib>Tomisawa, Kazuyuki</creatorcontrib><collection>CrossRef</collection><jtitle>British journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Okuyama, Shigeru</au><au>Chaki, Shigeyuki</au><au>Kawashima, Naoya</au><au>Suzuki, Yoshiko</au><au>Ogawa, Shin‐ichi</au><au>Kumagai, Toshihito</au><au>Nakazato, Atsuro</au><au>Nagamine, Masashi</au><au>Yamaguchi, Kazumasa</au><au>Tomisawa, Kazuyuki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The atypical antipsychotic profile of NRA0045, a novel dopamine D 4 and 5‐hydroxytryptamine 2A receptor antagonist, in rats</atitle><jtitle>British journal of pharmacology</jtitle><date>2009-02-10</date><risdate>2009</risdate><volume>121</volume><issue>3</issue><spage>515</spage><epage>525</epage><pages>515-525</pages><issn>0007-1188</issn><eissn>1476-5381</eissn><abstract>The atypical antipsychotic profile of ( R )‐(+)‐2‐amino‐4‐(4‐fluorophenyl)‐5‐[1‐[4‐(4‐fluorophenyl)‐4‐oxobutyl] pyrrolidin‐3‐yl] thiazole (NRA0045), a potent dopamine D 4 and 5‐hydroxytryptamine (5‐HT) 2A receptor antagonist, was examined in rats. Spontaneous locomotor activity was decreased dose‐dependently with i.p. administration of clozapine (ED 50 3.7 mg kg −1 ), haloperidol (ED 50 0.1 mg kg −1 ) and chlorpromazine (ED 50 0.9 mg kg −1 ), whereas inhibition of this type of behaviour induced by i.p. administration of NRA0045, at doses up to 10 mg kg −1 , did not exceed 50%. Locomotor hyperactivity induced by methamphetamine (MAP, 2 mg kg −1 , i.p.) in rats (a model of antipsychotic activity) was dose‐dependently antagonized by NRA0045 (ED 50 0.4 mg kg −1 , i.p., and 0.3 mg kg −1 , p.o., respectively), clozapine (ED 50 0.3 mg kg −1 , i.p. and 0.8 mg kg −1 , p.o., respectively), haloperidol (ED 50 0.02 mg kg −1 , i.p. and 0.1 mg kg −1 , p.o., respectively), chlorpromazine (ED 50 0.3 mg kg −1 , i.p. and 3.3 mg kg −1 , p.o., respectively). In contrast, the MAP (3 mg kg −1 , i.v.)‐induced stereotyped behaviour in rats (a model of extrapyramidal symptoms) was not affected by NRA0045 or clozapine, at the highest dose given (30 mg kg −1 , i.p.). Haloperidol (ED 50 0.3 mg kg −1 , i.p.) and chlorpromazine (ED 50 4.8 mg kg −1 , i.p.) strongly blocked the MAP‐induced stereotyped behaviour. NRA0045 and clozapine selectively blocked behaviour associated with activation of the mesolimbic/mesocortical dopamine neurones rather than nigrostriatal dopamine neurones. Extracellular single‐unit recording studies demonstrated that MAP (1 mg kg −1 , i.v.) decreased the firing rate in the substantia nigra (A9) and ventral tegmental area (A10) dopamine neurones in anaesthetized rats. NRA0045 completely reversed the inhibitory effects of MAP on A10 dopamine neurones (ED 50 0.1 mg kg −1 , i.v.), whereas the inhibitory effects of MAP on A9 dopamine neurones were not affected by NRA0045, in doses up to 1 mg kg −1 (i.v.). Clozapine completely reversed the inhibitory effects of MAP on A10 dopamine neurones (ED 50 1.9 mg kg −1 , i.v.) and on A9 dopamine neurones (ED 50 2.5 mg kg −1 , i.v.). Haloperidol completely reversed the inhibitory effects of MAP on A10 (ED 50 0.03 mg kg −1 , i.v.) and on A9 dopamine neurones (0.02 mg kg −1 , i.v.). NRA0045, like clozapine, was more potent in reversing the effects of MAP on A10 than A9 dopamine neurones. Prepulse inhibition (PPI) is impaired markedly in humans with schizophrenia. The disruption of PPI in rats by apomorphine (0.5 mg kg −1 , s.c.) was reversed significantly by NRA0045 (3 mg kg −1 , i.p.), clozapine (3 mg kg −1 , i.p.) and haloperidol (0.3 mg kg −1 , i.p.). Phencyclidine (PCP) elicits predominantly psychotic symptoms in normal humans and in schizophrenics. NRA0045 (0.03–0.3 mg kg −1 , i.p.) and clozapine (0.1–1 mg kg −1 , i.p.) significantly and dose‐dependently shortened the PCP(1.25 mg kg −1 , i.p.)‐induced prolonged swimming latency in rats in a water maze task, whereas haloperidol (0.01–0.1 mg kg −1 , i.p.) did not significantly alter swimming latency. These findings suggest that NRA0045 may have unique antipsychotic activities without the liability of motor side effects typical of classical antipsychotics.</abstract><doi>10.1038/sj.bjp.0701164</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0007-1188
ispartof British journal of pharmacology, 2009-02, Vol.121 (3), p.515-525
issn 0007-1188
1476-5381
language eng
recordid cdi_crossref_primary_10_1038_sj_bjp_0701164
source Wiley; PubMed Central
title The atypical antipsychotic profile of NRA0045, a novel dopamine D 4 and 5‐hydroxytryptamine 2A receptor antagonist, in rats
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T09%3A40%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20atypical%20antipsychotic%20profile%20of%20NRA0045,%20a%20novel%20dopamine%20D%204%20and%205%E2%80%90hydroxytryptamine%202A%20receptor%20antagonist,%20in%20rats&rft.jtitle=British%20journal%20of%20pharmacology&rft.au=Okuyama,%20Shigeru&rft.date=2009-02-10&rft.volume=121&rft.issue=3&rft.spage=515&rft.epage=525&rft.pages=515-525&rft.issn=0007-1188&rft.eissn=1476-5381&rft_id=info:doi/10.1038/sj.bjp.0701164&rft_dat=%3Ccrossref%3E10_1038_sj_bjp_0701164%3C/crossref%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c844-98d578226f9adcb091fcf232e61d35ae311f526c57072f396e74ff7b544e1cc03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true